Compare LVLU & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVLU | IXHL |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 35.4M |
| IPO Year | 2021 | 2024 |
| Metric | LVLU | IXHL |
|---|---|---|
| Price | $4.80 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $18.18 |
| AVG Volume (30 Days) | 7.5K | ★ 93.8K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $12,000.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $357.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $0.16 |
| 52 Week High | $32.32 | $6.39 |
| Indicator | LVLU | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 22.97 | 28.52 |
| Support Level | N/A | $0.16 |
| Resistance Level | $12.08 | $3.87 |
| Average True Range (ATR) | 1.01 | 0.21 |
| MACD | -0.64 | -0.02 |
| Stochastic Oscillator | 5.32 | 21.89 |
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.